Last reviewed · How we verify
Ebola Vaccine - mid dose
At a glance
| Generic name | Ebola Vaccine - mid dose |
|---|---|
| Also known as | Ebola Zaire Vaccine (2.5 x 10^5 pfu) |
| Sponsor | Auro Vaccines LLC |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of a New Vaccine Against Two Types of Ebola (PHASE1)
- Trial to Evaluate Safety and Immunogenicity of an Ebola Zaire Vaccine in Healthy Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ebola Vaccine - mid dose CI brief — competitive landscape report
- Ebola Vaccine - mid dose updates RSS · CI watch RSS
- Auro Vaccines LLC portfolio CI